MDNA.F Stock Overview
An immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Medicenna Therapeutics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.06 |
| 52 Week High | CA$2.20 |
| 52 Week Low | CA$0.28 |
| Beta | 1.19 |
| 11 Month Change | -32.24% |
| 3 Month Change | -33.52% |
| 1 Year Change | 239.87% |
| 33 Year Change | -48.19% |
| 5 Year Change | 1.63% |
| Change since IPO | -29.34% |
Recent News & Updates
Recent updates
Medicenna extends period to exercise certain warrants
Sep 30Medicenna, Merck enter clinical trial collaboration to evaluate combo cancer treatment
Sep 13Medicenna Therapeutics GAAP EPS of -$0.07 in-line
Aug 15Medicenna Therapeutics stock slides on launch of units offering
Aug 08Medicenna Therapeutics reports FY results
May 28Medicenna posts positive data from mid-stage brain cancer study
May 07Medicenna announces ATM sales facility for $25M
Dec 31Medicenna Therapeutics reports Q2 results
Nov 13Shareholder Returns
| MDNA.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.5% | -6.5% | -1.0% |
| 1Y | 239.9% | 14.6% | 30.3% |
Return vs Industry: MDNA.F exceeded the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: MDNA.F exceeded the US Market which returned 30.3% over the past year.
Price Volatility
| MDNA.F volatility | |
|---|---|
| MDNA.F Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MDNA.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MDNA.F's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 16 | Fahar Merchant | www.medicenna.com |
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops bizaxofusp (MDNA55), an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a masked bi-functional anti-PD1-IL2 Superkine for various solid tumors; and MDNA132, an IL-13 Superkine for various tumors.
Medicenna Therapeutics Corp. Fundamentals Summary
| MDNA.F fundamental statistics | |
|---|---|
| Market cap | US$83.93m |
| Earnings (TTM) | -US$19.10m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.4x
P/E RatioIs MDNA.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDNA.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$26.68m |
| Earnings | -CA$26.68m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MDNA.F perform over the long term?
See historical performance and comparison